The damage caused by anti-research legislation, especially that directed at therapeutic cloning, is well illustrated in this UPI article on Advanced Cell Technology. The threat of bans at federal and state levels in the US has scared away private funding and left companies like ACT limping along for years. "Due to a dearth of funding, Lanza said his company has been unable to follow up on promising results in animals and carry out experiments that could lead to life-saving therapies for humans. The financial situation is so dire, the company has at times been unable to afford basic office supplies." This has greatly held back progress in regenerative medicine and following up on promising laboratory work for age-related conditions.